The National Blood Authority (NBA) currently has supply arrangements in place for one plasma-derived Factor IX product, MonoFIX. Manufacture of this product has ceased, and MonoFIX will not be available for supply beyond June 2026.
There has been no demand for plasma-derived Factor IX since 2024 with all usage of this product type now transferred to recombinant Factor IX products.
The NBA will not be undertaking a new procurement process for an alternative plasma-derived Factor IX product. Multiple recombinant Factor IX products remain available under the national blood arrangements and are listed on the National Product Price List.
For further information, please contact CBP.Procurement@blood.gov.au.
Last updated: 07 Apr 2026